Bank of New York Mellon
SMMT icon

Bank of New York Mellon’s Summit Therapeutics SMMT Stock Holding History

Bank of New York Mellon’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.28M Buy
431,299
+26,620
+7% +$472K ﹤0.01% 2301
2026
Q1 		$7.67M Buy
404,679
+50,923
+14% +$824K ﹤0.01% 2069
2025
Q4 		$6.19M Sell
353,756
-13,370
-4% -$252K ﹤0.01% 2200
2025
Q3 		$7.58M Buy
367,126
+23,602
+7% +$572K ﹤0.01% 2090
2025
Q2 		$7.31M Buy
343,524
+2,749
+0.8% +$62.7K ﹤0.01% 2056
2025
Q1 		$6.57M Buy
340,775
+7,265
+2% +$146K ﹤0.01% 2069
2024
Q4 		$5.95M Buy
333,510
+84,117
+34% +$1.63M ﹤0.01% 2202
2024
Q3 		$5.46M Sell
249,393
-30,972
-11% -$433K ﹤0.01% 2254
2024
Q2 		$2.19M Sell
280,365
-21,334
-7% -$115K ﹤0.01% 2746
2024
Q1 		$1.25M Sell
301,699
-40,830
-12% -$162K ﹤0.01% 3030
2023
Q4 		$894K Buy
342,529
+24,199
+8% +$49.8K ﹤0.01% 3248
2023
Q3 		$595K Hold
318,330
– – ﹤0.01% 3454
2023
Q2 		$799K Buy
318,330
+272,892
+601% +$498K ﹤0.01% 3336
2023
Q1 		$79.5K Buy
45,438
+24,327
+115% +$66.3K ﹤0.01% 4109
2022
Q4 		$89.7K Buy
+21,111
New +$38.4K ﹤0.01% 4137
2022
Q2 		– Sell
-49,763
Closed -$122K – 4686
2022
Q1 		$122K Hold
49,763
– – ﹤0.01% 4368
2021
Q4 		$134K Buy
49,763
+4,971
+11% +$23.9K ﹤0.01% 4360
2021
Q3 		$224K Buy
44,792
+7,678
+21% +$55.1K ﹤0.01% 4162
2021
Q2 		$277K Buy
+37,114
New +$243K ﹤0.01% 3988
2020
Q1 		– Sell
-216,897
Closed -$347K – 4179
2019
Q4 		$347K Hold
216,897
– – ﹤0.01% 3745
2019
Q3 		$388K Hold
216,897
– – ﹤0.01% 3685
2019
Q2 		$274K Buy
216,897
+118,501
+120% +$198K ﹤0.01% 3832
2019
Q1 		$180K Buy
+98,396
New +$161K ﹤0.01% 3907

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of New York Mellon's SMMT Position: Q2 2026 in Review

Bank of New York Mellon increased its Summit Therapeutics (SMMT) stake by 6.6% in Q2 2026, buying an estimated $472K and bringing the position to 431,299 shares worth $6.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Bank of New York Mellon first reported a position in SMMT in Q1 2019 and has held it in 23 quarters since. The position peaked at $7.67M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Bank of New York Mellon held 431,299 shares of Summit Therapeutics worth $6.28M as of Q2 2026.
  • Bank of New York Mellon bought 26,620 Summit Therapeutics shares in Q2 2026, an estimated $472K.
  • Summit Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2301 holding.
  • Bank of New York Mellon first reported a position in Summit Therapeutics in Q1 2019 and has held it in 23 quarters since.
  • Bank of New York Mellon's Summit Therapeutics position peaked at $7.67M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.